Alterity Therapeutics (ASX:ATH)
ASX announcement history & article coverage
Transparent by design.
Announcments by Alterity Therapeutics (ASX:ATH) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Alterity to Present at Cantor Global Healthcare Conference
Change of Director's Interest Notice - Stamler
Change of Director's Interest Notice - Marks
Application for quotation of securities - ATH
Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC
$4.2M Options Underwriting Agreement Executed
Alterity Therapeutics secures underwriting for ATHO options to raise up to A$7.96 million
Application for quotation of securities - ATH
Corporate Governance Statement
Appendix 4G
Appendix 4E and 2026 Annual Report
Alterity Therapeutics reports increased revenue, larger net loss, and FDA-aligned Phase 3 trial plan for ATH434 in MSA
Application for quotation of securities - ATH
Disclosure Under Takeovers Panel GN 20
Application for quotation of securities - ATH
Granted New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics secures US patent for ATH434 extending protection to 2045, advancing Phase 3 plans
Application for quotation of securities - ATH
Alterity to Present at Canaccord Genuity Growth Conference
Application for quotation of securities - ATH
Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics secures FDA Phase 3 pathway for ATH434 in MSA, plans trial start by end 2026
Upcoming Expiry of ATHO Listed Options
Application for quotation of securities - ATH
Alterity to Participate in the BTIG Biotechnology Conference
Application for quotation of securities - ATH
ATH Receives A$3.98m R&D Tax Incentive
Alterity Therapeutics Receives A$3.98m R&D Tax Incentive Refund
Application for quotation of securities - ATH
FDA Meeting Minutes Confirm Registrational Path for ATH434
FDA Confirms Registrational Pathway for Alterity's ATH434 in Multiple System Atrophy
Application for quotation of securities - ATH
Change in substantial holding
Change of Director's Interest Notice x 2
Corporate Presentation June 2026
Notification regarding unquoted securities - ATH
Notification of cessation of securities - ATH
Completion of Consolidation
Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
Alterity Therapeutics Secures FDA Alignment on Phase 3 Trial Design for ATH434 in Multiple System Atrophy
